Vycor Medical (VYCO) EBITDA Margin (2010 - 2026)

Vycor Medical (VYCO) has 17 years of EBITDA Margin data on file, last reported at 9.99% in Q1 2026.

• On a quarterly basis, EBITDA Margin rose 1292.0% year-over-year to 9.99% in Q1 2026; TTM through Mar 2026 was 4.91%, a 564.0% increase from a year earlier, with the FY2025 full-year figure at 1.82%, up 239.0% from the prior year.
• EBITDA Margin for Q1 2026 stood at 9.99%, up from 8.76% in the prior quarter.
• Over the last five years, EBITDA Margin for VYCO reached as high as 19.99% in Q2 2023 and fell as low as 33.62% in Q4 2022.
• Historically, EBITDA Margin has averaged 5.3% across 5 years, with a median of 2.93% in 2025.
• On a YoY basis, EBITDA Margin climbed as much as 5308 bps in 2022 and fell as far as 2746 bps in 2022.
• Year by year, EBITDA Margin stood at 33.62% in 2022, then jumped by 38 bps to 20.78% in 2023, then soared by 120 bps to 4.25% in 2024, then plunged by 306 bps to 8.76% in 2025, then surged by 214 bps to 9.99% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 9.99% in Q1 2026, 8.76% in Q4 2025, and 6.24% in Q3 2025.